# Gastroenterology

www.gastrojournal.org Vol. 155, No. 6 December 2018


TABLE OF CONTENTS

## Contents

### ON THE COVER


**See the article by Engevik et al on page 1883 for additional information.**



(V) Video (CGH) Related article in *CGH* Hot Papers From New Investigators
(CME) CME quiz (E) Editorial accompanies this article (WWW) Additional online content available (COV) Cover


**Publisher:** *Gastroenterology* **(ISSN 0016-5085) is published monthly (semi monthly in January and May) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2018 US subscription rates: individual, $711.00; student and resident, $271.00. Outside of the U.S. and possessions: individual, $968.00; student and resident, $562.00; surface delivery, no additional charge; air mail delivery, add $78.00. Prices subject to change without notice.**

## EDITORIALS



## GASTROENTEROLOGY IN MOTION



## CLINICAL CHALLENGES AND IMAGES IN GI



## ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GI

**For a full list, please see the table of contents online at www.gastrojournal.org.**

## PRACTICAL TEACHING CASE



## REVIEWS AND PERSPECTIVES

### Brief Review



## ORIGINAL RESEARCH

### Brief Report



The incidence of colorectal cancer is increasing in younger (age <50 years) adults. In contrast, a clear pattern of *declining* incidence rates from 1975 through 1990 was found.

### Full Reports

#### Clinical—Alimentary Tract



There are two potential types of esophageal adenocarcinoma based on the presence or absence of Barrett's esophagus in the background that determine prognosis with improved survival in Barrett's patients.



An externally validated clinical model estimated pre-test probability of abnormal pH in patients who have failed PPI therapy, which can help clinicians determine diagnostic testing strategies for these patients.



FXR-dependent suppression of bile acids in humans leads to a reversible induction of bacteria inhibited by bile acids, found in the small intestine, and are components of the diet.



**See editorial on page 1677.**

In a network meta-analysis comparing 15 trials of secretagogues, containing 8462 patients with IBS-C, Linaclotide 290 mcg once-daily was ranked first for efficacy for almost all endpoints.

## Clinical—Liver

## Basic and Translational—Liver



## Basic and Translational—Pancreas